Effect of 5-aminosalicylic acid and analogous substances on superoxide generation and intracellular free calcium in human neutrophilic granulocytes

Research output: Contribution to journalJournal articleResearchpeer-review

Activated polymorphonuclear leukocytes (PMNs), which are found in the inflammatory lesions of chronic inflammatory bowel disease, produce tissue-destructive oxygen-derived free radicals. The influence of 5-aminosalicylic acid (5-ASA), its acetylated metabolite (Ac-5-ASA), sulfasalazine (SAZ), and olsalazine (OLZ) (5-ASA dimer linked by an azo group) in pharmacologically relevant concentrations (0.1-10 mM) were tested on PMN superoxide production with either the receptor-specific agent formyl-methionyl-leucyl-phenylalanine (fMLP) or the protein kinase C activator phorbol myristate acetate (PMA). Inhibition of receptor-specific superoxide production occurred at 0.07, 0.32, and 0.63 mM (IC50 values) for 5-ASA, SAZ, and OLZ, respectively. No inhibitory effects of SAZ and OLZ were observed when PMA was applied as stimulus for PMN superoxide production. The results indicate that the signal to which PMNs respond by generating superoxide is primarily due to calcium release from intracellular stores. They further suggest that SAZ and OLZ may affect the oxygen-derived free radical production in human PMNs by unspecific cytotoxicity or by interference with the nicotinamide adenine dinucleotide phosphate, reduced (NADPH) oxidase system, whereas 5-ASA itself is a free radical scavenger.

Original languageEnglish
Book seriesScandinavian Journal of Gastroenterology
Volume28
Issue number6
Pages (from-to)527-32
Number of pages6
ISSN0036-5521
Publication statusPublished - Jun 1993

    Research areas

  • Aminosalicylic Acids/pharmacology, Calcium/metabolism, Free Radical Scavengers, Free Radicals, Humans, In Vitro Techniques, Mesalamine, N-Formylmethionine Leucyl-Phenylalanine/pharmacology, Neutrophils/drug effects, Sulfapyridine/pharmacology, Sulfasalazine/pharmacology, Superoxides/metabolism, Tetradecanoylphorbol Acetate/pharmacology

ID: 218727515